Peptide pens and vials: reading the label

A practical UK reference for comparing peptide names, labelled strengths, presentation formats and supporting laboratory documentation. Packaging is a starting point for identification, not proof of a product’s contents or clinical suitability.

By Manchester Peptides · Published 26 October 2026 · Updated 2 November 2026

Start with the compound, then the format

Searches for peptide pens, research vials or peptides UK often mix together three different questions: which molecule is named, how it is presented and what evidence supports it. Read those in that order. A pen and a vial may share a compound name while differing in formulation, total content, volume or documentation. The presentation does not make them analytically or medically equivalent.

For example, the Retatrutide profile identifies the listed pen and vial formats. The separate Retatrutide research guide discusses the molecule and evidence. The Tirzepatide profile is another listing, for a distinct molecule; a similar-looking box does not make the two interchangeable.

Total amount is different from concentration

A label stating 40 mg identifies an intended total amount. A label stating mg/mL identifies a concentration. Neither statement independently verifies what is present. When comparing listings, check whether the number refers to one container, a complete set or an individual component of a mixture.

Volume and total amount should be clearly distinguished on the original label. If either is unclear, do not infer it from a photograph, a pen’s appearance or the number in a product name. This guide does not calculate doses, pen clicks, dilution or administration instructions.

What does Wolverine mean on a BPC-157 pen?

Wolverine is an informal commercial name commonly used for BPC-157 with TB-500. It is not a standard approved medicinal formulation. A label saying 10 mg + 10 mg identifies two component amounts; it is not a claim that each component is present at 20 mg. The exact identity of TB-500-related material also needs documentation rather than an assumption based on its name.

Use the BPC-157 + TB-500 format profile for the listing and the BPC-157 and TB-500 evidence guide for the limits of the research. A blend report should make clear which components were identified or quantified.

Blend names and abbreviations need an ingredient record

KLOW is a catalogue blend name. Check the full ingredient list and individual amounts instead of treating the name as a universal specification. Similarly, GHK-Cu refers to a copper-binding peptide complex, while MOTS-C is a different peptide associated with mitochondrial signalling research. NAD+ is a coenzyme, not a peptide. Grouping these entries in one catalogue does not make them chemically alike.

CJC-1295 is another example where a fuller identity matters: entries described with DAC and without DAC should not be treated as automatically equivalent. Search results for a CJC-1295 pen do not establish that such a format is currently supplied here. Check the exact entry in the A–Z reference catalogue and the current pen collection separately.

Use box images as reference, not authentication

A packaging photograph helps visitors recognise the displayed format and read its label. It cannot establish the chemical identity, fill amount, sterility, storage history or provenance of an individual item. A product image may also differ from a later packaging revision. Compare names and strengths with the current written entry, and resolve any conflicting ingredient statements before relying on either.

What should “best peptides” mean when checking information?

A broad “best” claim is not a substitute for a defined question. Useful documentation is specific: an exact identity, an understandable formulation, traceable sample details, suitable analytical methods and results shown with their limitations. A high purity percentage is one finding, not an overall quality or safety score.

The COA checklist helps organise those questions. Keep the labelled strength separate from the measured laboratory result. Read the purity, identity, content and sterility guide for why separate tests answer separate questions.

UK reference information and authorised medicines

UK location, a research label, a familiar molecule name or pen-style packaging does not establish authorisation as a medicine. Evidence for an authorised product cannot simply be transferred to unrelated research-labelled material. These pages identify catalogue formats and explain scientific information; they do not recommend personal use or replace a regulated clinical supply route.

Continue with the peptide evidence index, named-sample report library or editorial policy to examine the evidence behind a description.